AstraZeneca: FDA to Review Hyperkalaemia Drug
October 18 2016 - 3:00AM
Dow Jones News
By Tapan Panchal
LONDON--Pharmaceutical company AstraZeneca PLC (AZN.LN) said
Tuesday the U.S. Food and Drug Administration accepted a complete
re-submission of a new drug application for a potential new
medicine for treating high potassium levels in the human body.
The regulator accepted a new application for sodium zirconium
cyclosilicate, or ZS-9, used for treating hyperkalaemia, it said.
The new application was submitted by the company's unit ZS
Pharma.
Write to Tapan Panchal at tapan.panchal@wsj.com
(END) Dow Jones Newswires
October 18, 2016 02:45 ET (06:45 GMT)
Copyright (c) 2016 Dow Jones & Company, Inc.
AstraZeneca (NYSE:AZN)
Historical Stock Chart
From Apr 2024 to May 2024
AstraZeneca (NYSE:AZN)
Historical Stock Chart
From May 2023 to May 2024